Differences in the HbA1c-lowering efficacy of glucagon-like peptide-1 analogues between Asians and non-Asians: a systematic review and meta-analysis (Q38198185)

From Wikidata

Jump to navigation Jump to search

scientific article published on 15 April 2014

Language	Label	Description	Also known as
English	Differences in the HbA1c-lowering efficacy of glucagon-like peptide-1 analogues between Asians and non-Asians: a systematic review and meta-analysis	scientific article published on 15 April 2014

Statements

scholarly article

1 reference

Europe PubMed Central

30 August 2017

0 references

1 reference

Europe PubMed Central

Differences in the HbA1c-lowering efficacy of glucagon-like peptide-1 analogues between Asians and non-Asians: a systematic review and meta-analysis (English)

1 reference

Europe PubMed Central

30 August 2017

systematic review

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Y G Kim

1

1 reference

Europe PubMed Central

30 August 2017

S Hahn

2

1 reference

Europe PubMed Central

30 August 2017

T J Oh

3

1 reference

Europe PubMed Central

30 August 2017

K S Park

4

1 reference

Europe PubMed Central

30 August 2017

Y M Cho

5

1 reference

Europe PubMed Central

30 August 2017

publication date

15 April 2014

1 reference

Europe PubMed Central

30 August 2017

Diabetes, Obesity and Metabolism

1 reference

Europe PubMed Central

30 August 2017

16

1 reference

Europe PubMed Central

30 August 2017

900-909

1 reference

Europe PubMed Central

30 August 2017

10

1 reference

Europe PubMed Central

30 August 2017

Diabetes in Asia: epidemiology, risk factors, and pathophysiology

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12293

21 January 2018

Ethnic differences in the relationship between insulin sensitivity and insulin response: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12293

21 January 2018

Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12293

21 January 2018

Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12293

21 January 2018

Targeting the glucagon receptor family for diabetes and obesity therapy

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12293

21 January 2018

One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12293

21 January 2018

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12293

21 January 2018

GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12293

21 January 2018

Once weekly exenatide: efficacy, tolerability and place in therapy

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12293

21 January 2018

Liraglutide - overview of the preclinical and clinical data and its role in the treatment of type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12293

21 January 2018

Exenatide: a review from pharmacology to clinical practice

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12293

21 January 2018

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12293

21 January 2018

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12293

21 January 2018

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12293

21 January 2018

Exenatide exhibits dose-dependent effects on glycemic control over 12 weeks in Japanese patients with suboptimally controlled type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12293

21 January 2018

Improved glycemic control and reduced bodyweight with exenatide: A double-blind, randomized, phase 3 study in Japanese patients with suboptimally controlled type 2 diabetes over 24 weeks

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12293

21 January 2018

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12293

21 January 2018

Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12293

21 January 2018

Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12293

21 January 2018

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12293

21 January 2018

Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12293

21 January 2018

The effects of LY2189265, a long-acting glucagon-like peptide-1 analogue, in a randomized, placebo-controlled, double-blind study of overweight/obese patients with type 2 diabetes: the EGO study.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12293

21 January 2018

Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD).

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12293

21 January 2018

Efficacy and safety of taspoglutide versus sitagliptin for type 2 diabetes mellitus (T-emerge 4 trial).

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12293

21 January 2018

Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono)

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12293

21 January 2018

Monotherapy with the once-weekly GLP-1 analogue dulaglutide for 12 weeks in patients with Type 2 diabetes: dose-dependent effects on glycaemic control in a randomized, double-blind, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12293

21 January 2018

Efficacy and safety of taspoglutide in patients with type 2 diabetes inadequately controlled with metformin plus pioglitazone over 24 weeks: T-Emerge 3 trial

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12293

21 January 2018

Improved glycaemic control with minimal hypoglycaemia and no weight change with the once-daily human glucagon-like peptide-1 analogue liraglutide as add-on to sulphonylurea in Japanese patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12293

21 January 2018

Efficacy and safety of taspoglutide monotherapy in drug-naive type 2 diabetic patients after 24 weeks of treatment: results of a randomized, double-blind, placebo-controlled phase 3 study (T-emerge 1)

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12293

21 January 2018

The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12293

21 January 2018

Effects of exenatide plus rosiglitazone on beta-cell function and insulin sensitivity in subjects with type 2 diabetes on metformin

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12293

21 January 2018

Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia).

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12293

21 January 2018

A placebo-controlled trial of exenatide twice-daily added to thiazolidinediones alone or in combination with metformin

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12293

21 January 2018

Efficacy and safety of exenatide in patients of Asian descent with type 2 diabetes inadequately controlled with metformin or metformin and a sulphonylurea

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12293

21 January 2018

Efficacy and safety of dipeptidyl peptidase-4 inhibitors in type 2 diabetes: meta-analysis.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12293

21 January 2018

Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12293

21 January 2018

Clinical characteristics of the responders to dipeptidyl peptidase-4 inhibitors in Korean subjects with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12293

21 January 2018

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12293

21 January 2018

Effect of Single Oral Doses of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on Incretin and Plasma Glucose Levels after an Oral Glucose Tolerance Test in Patients with Type 2 Diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12293

21 January 2018

GLP-1 receptor agonists and HBA1ctarget of <7% in type 2 diabetes: meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12293

21 January 2018

Identifiers

10.1111/DOM.12293

1 reference

Europe PubMed Central

30 August 2017

1 reference

Europe PubMed Central

30 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38198185&oldid=2102167077"